1. Syngene Q1 Net up 28 per cent at Rs 60 cr

Syngene Q1 Net up 28 per cent at Rs 60 cr

Biocon's contract research and manufacturing arm Syngene International today reported 28.32 per cent rise in standalone net profit to Rs 59.8 crore for the quarter ended on June 30, 2016.

By: | New Delhi | Published: July 21, 2016 9:02 PM
Biocon shares - cancer drug The company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a filing to BSE. (Reuters)

Biocon’s contract research and manufacturing arm Syngene International today reported 28.32 per cent rise in standalone net profit to Rs 59.8 crore for the quarter ended on June 30, 2016.

The company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a filing to BSE.

Standalone total income from operations of the company also rose to Rs 274.5 crore for the quarter ended June, 2016 as against Rs 233.7 crore for the same period year ago.

“We are pleased to report a good start for the year with all our three verticals performing as expected… two new facilities are now operational– the first phase of the Syngene Research Centre and viral testing facility,” Syngene International CEO Jonathan Hunt said.

Shares of Syngene International today closed at Rs 427.75 on BSE, up 1.21 per cent from its previous close.

  1. No Comments.

Go to Top